Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients 

Authors: Gaye Hafez, Jolanta Malyszko, Aleksandra Golenia, Aleksandra Klimkowicz-Mrowiec, Ana Carina Ferreira, Mustafa Arıcı, Annette Bruchfeld, Dorothea Nitsch, Ziad A Massy, Marion Pépin, 

Giovambattista Capasso, Laila-Yasmin Mani, Sophie Liabeuf, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)

The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.

View publication here.

Latest Updates


MC meeting

SAVE THE DATE: The next MC meeting will be held in Lithuania on 25-26 June 2024.

Read More

Brain-Kidney Interaction-The brain and kidney

Many CONNECT members took part in the symposium called “Brain-Kidney Interaction-The brain and kidney: from physiology to clinics”, which took place in Naples on 23-24 November 2023, with their speeches.

Read More

Fourth Call for Short-Term Scientific Mission

Fourth Call for Short-Term Scientific Mission (STSM) applications within the COST Action “Cognitive decline in Nephro-Neurology: European Cooperative Target (CONNECT)” Deadline for submission: November 30th, 2023

Read More